Article
Version 1
Preserved in Portico This version is not peer-reviewed
Can Semaglutide Bind Tighter to GLP-1R?
*
Version 1
: Received: 23 July 2020 / Approved: 24 July 2020 / Online: 24 July 2020 (11:58:41 CEST)
How to cite: Li, W. Can Semaglutide Bind Tighter to GLP-1R?. Preprints 2020, 2020070582. https://doi.org/10.20944/preprints202007.0582.v1 Li, W. Can Semaglutide Bind Tighter to GLP-1R?. Preprints 2020, 2020070582. https://doi.org/10.20944/preprints202007.0582.v1
Abstract
Semaglutide is a glucagon-like peptide 1 analog used for the treatment of patients with type 2 diabetes mellitus. With 94% sequence similarity to human GLP-1, semaglutide is a glucagon-like peptide-1 receptor (GLP-1R) agonist, which binds directly to GLP-1R, causing various beneficial downstream effects that reduce blood glucose. Practically, it is favourable for semaglutide to bind not just directly, but also tighter, to its receptor GLP-1R. Therefore, incorporating currently available experimental structural data of semaglutide-GLP-1R, this short article reports for the first time that biophysically, semaglutide is able to bind tighter to GLP-1R with just a simple Val27-Arg28 exchange in its peptide backbone.
Keywords
Semaglutide; GLP-1R; Interfacial Biophysics
Subject
Biology and Life Sciences, Biophysics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
